Yuko Oya
Overview
Explore the profile of Yuko Oya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
679
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamatsuta K, Okachi S, Hasegawa S, Ota M, Kako H, Ina T, et al.
BMC Pulm Med
. 2024 Dec;
24(1):632.
PMID: 39725905
Background: The increasing prevalence of lung cancer in the elderly population necessitates a closer evaluation of diagnostic and therapeutic approaches. This study aimed to compare the safety and diagnostic efficacy...
2.
Akao K, Oya Y, Sato T, Ikeda A, Horiguchi T, Goto Y, et al.
Explor Target Antitumor Ther
. 2024 Sep;
5(4):826-840.
PMID: 39280252
Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantly. Accumulating...
3.
Kawachi H, Tamiya M, Oya Y, Saito G, Taniguchi Y, Matsumoto H, et al.
Clin Lung Cancer
. 2024 Aug;
25(7):643-652.e4.
PMID: 39138106
Background: The optimal subsequent treatment strategy for locally advanced non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy (CRT) and consolidative durvalumab therapy remains unknown. We aimed to determine the optimal subsequent...
4.
Oya Y, Imaizumi K, Mitsudomi T
Lung Cancer
. 2024 Jul;
194:107886.
PMID: 39047616
The Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the first driver oncogenes identified in human cancer in the early 1980s. However, it has been deemed 'undruggable' for...
5.
Lee J, Huang Y, Oya Y, Nutzinger J, LE Ang Y, Sooi K, et al.
Lung Cancer
. 2024 Jul;
194:107862.
PMID: 38959670
Despite the efficacy of immunotherapy in non-small cell lung cancer (NSCLC), the majority of the patients experience relapse with limited subsequent treatment options. Preclinical studies of various epithelial tumors, such...
6.
Nishio M, Murakami S, Kawakami H, Okishio K, Tamiya M, Kobayashi H, et al.
Cancer Res Commun
. 2024 Jan;
4(1):226-235.
PMID: 38181055
Purpose: E7389-LF is a liposomal formulation of eribulin that contributes to tumor vascular remodeling. The phase II part of this phase Ib/II study assessed the efficacy/safety of E7389-LF in combination...
7.
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, et al.
Lung Cancer
. 2023 Dec;
188:107450.
PMID: 38160082
No abstract available.
8.
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, et al.
Lung Cancer
. 2023 Nov;
186:107426.
PMID: 37992594
Objectives: Osimertinib is the primary treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer. However, evidence of the outcomes of osimertinib treatment in patients...
9.
Lim S, Lee J, Oya Y, Nutzinger J, Soo R
JCO Oncol Pract
. 2023 Sep;
20(1):47-56.
PMID: 37733983
Over the past decade, tremendous efforts have been made in the development of targeted agents in non-small-cell lung cancer (NSCLC) with nonsquamous histology. Pivotal studies have used next-generation sequencing to...
10.
Oya Y, Mitsudomi T
Transl Lung Cancer Res
. 2023 Jun;
12(5):940-943.
PMID: 37323182
No abstract available.